Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States.
Flawless balance sheet with outstanding track record.
Share Price & News
How has Palatin Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: PTNA's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: PTNA underperformed the German Biotechs industry which returned 2.8% over the past year.
Return vs Market: PTNA underperformed the German Market which returned 6.5% over the past year.
Price Volatility Vs. Market
How volatile is Palatin Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Palatin Technologies undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PTNA (€0.43) is trading below our estimate of fair value (€3.11)
Significantly Below Fair Value: PTNA is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PTNA is good value based on its PE Ratio (3.1x) compared to the Biotechs industry average (37.6x).
PE vs Market: PTNA is good value based on its PE Ratio (3.1x) compared to the German market (20x).
Price to Earnings Growth Ratio
PEG Ratio: PTNA's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: PTNA is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.2x).
How is Palatin Technologies forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTNA's earnings are forecast to decline over the next 3 years (-6.3% per year).
Earnings vs Market: PTNA's earnings are forecast to decline over the next 3 years (-6.3% per year).
High Growth Earnings: PTNA's earnings are forecast to decline over the next 3 years.
Revenue vs Market: PTNA's revenue is expected to decline over the next 3 years (-6% per year).
High Growth Revenue: PTNA's revenue is forecast to decline over the next 3 years (-6% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PTNA's Return on Equity is forecast to be high in 3 years time
How has Palatin Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PTNA has high quality earnings.
Growing Profit Margin: PTNA's current net profit margins (60.9%) are higher than last year (1.2%).
Past Earnings Growth Analysis
Earnings Trend: PTNA has become profitable over the past 5 years, growing earnings by 52.2% per year.
Accelerating Growth: PTNA's earnings growth over the past year (10568.9%) exceeds its 5-year average (52.2% per year).
Earnings vs Industry: PTNA earnings growth over the past year (10568.9%) exceeded the Biotechs industry -4.7%.
Return on Equity
High ROE: PTNA's Return on Equity (40.2%) is considered outstanding.
Return on Assets
Return on Capital Employed
How is Palatin Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: PTNA's short term assets ($92.2M) exceed its short term liabilities ($1.4M).
Long Term Liabilities: PTNA's short term assets ($92.2M) exceed its long term liabilities ($13.5K).
Debt to Equity History and Analysis
Debt Level: PTNA is debt free.
Reducing Debt: PTNA has no debt compared to 5 years ago when its debt to equity ratio was 29.9%.
Inventory Level: PTNA has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if PTNA's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PTNA is profitable, therefore cash runway is not a concern.
Forecast Cash Runway: PTNA is profitable, therefore cash runway is not a concern.
What is Palatin Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate PTNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate PTNA's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PTNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PTNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of PTNA's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Carl Spana (57yo)
Dr. Carl Spana, Ph.D., is a Co-Founder of Palatin Technologies Inc and has been its Chief Executive Officer and President since June 14, 2000. From June 1996 to June 14, 2000, Dr. Spana served as an Chief ...
CEO Compensation Analysis
Compensation vs Market: Carl's total compensation ($USD2.27M) is above average for companies of similar size in the German market ($USD415.71K).
Compensation vs Earnings: Carl's compensation has been consistent with company performance over the past year.
|Co-Founder & Non-Executive Chairman||19.7yrs||US$267.90k||0.14% $130.7k|
|Independent Director||4.7yrs||US$138.30k||0.066% $63.7k|
|Independent Director||21.3yrs||US$148.30k||0.091% $88.0k|
|Independent Director||8.7yrs||US$170.18k||0.075% $72.5k|
|Independent Director||2.4yrs||US$130.80k||0.018% $17.5k|
|Member of Female Sexual Dysfunction Expert Panel||0yrs||no data||no data|
|Member of Female Sexual Dysfunction Expert Panel||0yrs||no data||no data|
|Independent Director||14.4yrs||US$140.80k||0.071% $68.1k|
|Independent Director||6.7yrs||US$138.30k||0.067% $65.0k|
Experienced Board: PTNA's board of directors are seasoned and experienced ( 11.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.2%.
Palatin Technologies, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Palatin Technologies, Inc.
- Ticker: PTNA
- Exchange: DB
- Founded: 1986
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$106.070m
- Listing Market Cap: US$96.449m
- Shares outstanding: 229.24m
- Website: https://www.palatin.com
Number of Employees
- Palatin Technologies, Inc.
- Cedar Brook Corporate Center
- 4B Cedar Brook Drive
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|PTN||AMEX (NYSE MKT LLC)||Yes||Common Stock||US||USD||Oct 1993|
|PTNA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Oct 1993|
|0KF3||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Oct 1993|
Palatin Technologies, Inc., a specialized biopharmaceutical company, develops targeted receptor-specific product candidates for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor agonist, which has completed Phase III trial for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. It is also developing oral PL8177, a selective melanocortin receptor 1 (MCr) agonist peptide that has completed Phase I clinical trial for inflammatory bowel diseases; and systemic PL8177, which has completed Phase I clinical trial for treating non-infectious uveitis. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease. Further, it is involved in developing MC4r agonist peptide and small molecule for the treatment of rare genetic metabolic and obesity disorders. Additionally, the company engages in the development of PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, a dual NPR-A and NPR-C agonist to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. Palatin Technologies, Inc. was founded in 1986 and is based in Cranbury, New Jersey.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 21:16|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.